|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
1992-12-4
|
|
pubmed:abstractText |
Each of the dynorphin A(1-13) or dynorphin (dyn) treatment groups receiving naloxone showed a significant overall reduction of overt signs compared with the dyn controls. The data suggested that the overt psychomotor effects of dyn in the rhesus monkey were especially prone to blockade by naloxone, and probably involved opioid mechanisms.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0196-9781
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
13
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
847-9
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
|
|
pubmed:articleTitle |
Blockade of dynorphin A(1-13) overt psychomotor effects by naloxone.
|
|
pubmed:affiliation |
Department of Pharmacology and Toxicology, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298-0613.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|
